<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alphamab Oncology — News on 6ix</title>
<link>https://6ix.com/company/alphamab-oncology</link>
<description>Latest news and press releases for Alphamab Oncology on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 06:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alphamab-oncology" rel="self" type="application/rss+xml" />
<item>
<title>2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation</title>
<link>https://6ix.com/company/alphamab-oncology/news/2026-asco-preview-or-results-from-phase-iii-study-of-anbenitamab-kn026-combined-with-hb1801-in-neoadjuvant-treatment-for-breast-cancer-selected-for-lba-oral-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/2026-asco-preview-or-results-from-phase-iii-study-of-anbenitamab-kn026-combined-with-hb1801-in-neoadjuvant-treatment-for-breast-cancer-selected-for-lba-oral-presentation</guid>
<pubDate>Wed, 22 Apr 2026 06:10:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with albumin-bound Docetaxel for Injection (HB1801) from CSPC as neoadjuvant treatment of breast cancer, have been</description>
</item>
<item>
<title>Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-phase-iii-clinical-study-of-anbenitamab-kn026-combined-with-hb1801-as-neoadjuvant-treatment-for-breast-cancer-has-met-the-primary-endpoint</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-phase-iii-clinical-study-of-anbenitamab-kn026-combined-with-hb1801-as-neoadjuvant-treatment-for-breast-cancer-has-met-the-primary-endpoint</guid>
<pubDate>Wed, 01 Apr 2026 14:44:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with Docetaxel for Injection (Albumin-bound) (HB1801), has met the pre-specified primary endpoint of total pathological complete response (tpCR) in a Phase III clinical study (KN026-004) f</description>
</item>
<item>
<title>Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-reports-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-reports-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Thu, 26 Mar 2026 05:13:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress.</description>
</item>
<item>
<title>Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-of-anbenitamab-kn026-combined-with-hb1801-and-chemotherapy-as-adjuvant-treatment-of-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-of-anbenitamab-kn026-combined-with-hb1801-and-chemotherapy-as-adjuvant-treatment-of-breast-cancer</guid>
<pubDate>Tue, 24 Mar 2026 01:32:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN026) in combination with albumin-bound docetaxel (HB1801) and chemotherapy as adjuvant treatment for HER2-positive breast cancer (BC). Anbenitamab (KN026) is independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (sto</description>
</item>
<item>
<title>Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-triple-negative-breast-cancer-of-trop2her3-bispecific-adc-jskn016</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-triple-negative-breast-cancer-of-trop2her3-bispecific-adc-jskn016</guid>
<pubDate>Fri, 20 Mar 2026 02:04:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC). This milestone brings another innovative bispecific ADC from the company's pipeline into pivotal development, reinforcing its potential to offer a more effective and safer treatment option for patients with TNBC.</description>
</item>
<item>
<title>Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-appoints-mr-fei-wang-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-appoints-mr-fei-wang-as-chief-financial-officer</guid>
<pubDate>Wed, 18 Mar 2026 13:43:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) today announced the appointment of Mr. Fei Wang as Chief Financial Officer (CFO). Mr. Wang will be responsible for the company's capital operations, investment and financing management and investor relations, and report to Dr. Ting Xu, Chairman and CEO of Alphamab Oncology. Mr. Wang has accumulated over 20 years of professional experience in financial management and capital markets, with more than 15 years dedicated to the biopharmaceutical industry in Chi</description>
</item>
<item>
<title>Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-i-clinical-study-of-pd-l1vegfr2-bispecific-adc-jskn027</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-i-clinical-study-of-pd-l1vegfr2-bispecific-adc-jskn027</guid>
<pubDate>Tue, 17 Mar 2026 02:32:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company's fifth ADC candidate entering clinical development, as well as the world's first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials.</description>
</item>
<item>
<title>Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-ind-application-for-innovative-egfrher3-dual-payload-bispecific-adc-jskn021-was-officially-accepted-by-cde</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-ind-application-for-innovative-egfrher3-dual-payload-bispecific-adc-jskn021-was-officially-accepted-by-cde</guid>
<pubDate>Fri, 13 Mar 2026 01:53:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical study of JSKN021 for the treatment of advanced malignant solid tumors.</description>
</item>
<item>
<title>Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-appoints-dr-hongwei-wang-as-chief-technology-officer</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-appoints-dr-hongwei-wang-as-chief-technology-officer</guid>
<pubDate>Wed, 11 Mar 2026 01:38:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced the appointment of Dr. Hongwei Wang as Chief Technology Officer (CTO). Dr. Wang will be responsible for the company's Process Development and Analytical Development Department, Production Department and Quality Department, and report to Dr. Ting Xu, Chairman and CEO of Alphamab Oncology. Dr. Hongwei Wang is a seasoned expert in biopharmaceutical CMC (Chemistry, Manufacturing, and Controls) development and commercial manufacturing management, with</description>
</item>
<item>
<title>Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-colorectal-cancer-of-biparatopic-her2-targeting-adc-jskn003</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-colorectal-cancer-of-biparatopic-her2-targeting-adc-jskn003</guid>
<pubDate>Sat, 14 Feb 2026 12:58:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of HER2-positive advanced colorectal cancer (CRC). JSKN003 is independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK).</description>
</item>
<item>
<title>Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-results-of-a-phase-iii-clinical-study-of-anbenitamab-kn026-were-published-in-annals-of-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-results-of-a-phase-iii-clinical-study-of-anbenitamab-kn026-were-published-in-annals-of-oncology</guid>
<pubDate>Tue, 27 Jan 2026 01:58:00 GMT</pubDate>
<description>Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), were recently published in the top-tier oncology journal Annals of Oncology (IF:65.4). The publicati</description>
</item>
<item>
<title>Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-ind-application-for-a-phase-ii-clinical-study-of-her2-bispecific-adc-subcutaneous-co-formulation-jskn033-as-first-line-treatment-of-advanced-cervical-cancer-was-officially-accepted-by-cde</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-ind-application-for-a-phase-ii-clinical-study-of-her2-bispecific-adc-subcutaneous-co-formulation-jskn033-as-first-line-treatment-of-advanced-cervical-cancer-was-officially-accepted-by-cde</guid>
<pubDate>Mon, 29 Dec 2025 05:52:00 GMT</pubDate>
<description>Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor) in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment of advanced cervical cancer (Study Number: JSKN033-202), has been officially accepted by the Center for Drug Evaluation (CD</description>
</item>
<item>
<title>Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-was-granted-breakthrough-therapy-designation-by-the-fda-for-the-treatment-of-proc</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-was-granted-breakthrough-therapy-designation-by-the-fda-for-the-treatment-of-proc</guid>
<pubDate>Sat, 20 Dec 2025 04:54:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced or metastatic platinum-resistant recurrent</description>
</item>
<item>
<title>Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-ind-application-for-innovative-pd-l1-vegfr2-bispecific-adc-jskn027-was-officially-accepted-by-cde</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-ind-application-for-innovative-pd-l1-vegfr2-bispecific-adc-jskn027-was-officially-accepted-by-cde</guid>
<pubDate>Thu, 18 Dec 2025 02:26:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical study of JSKN027 for the treatment of advanced malignant solid tumors.</description>
</item>
<item>
<title>Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held</title>
<link>https://6ix.com/company/alphamab-oncology/news/stay-true-to-our-original-aspiration-forge-ahead-into-the-futurealphamab-oncology-2025-randd-day-successfully-held</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/stay-true-to-our-original-aspiration-forge-ahead-into-the-futurealphamab-oncology-2025-randd-day-successfully-held</guid>
<pubDate>Wed, 10 Dec 2025 06:20:00 GMT</pubDate>
<description>On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The event focused on the latest advancements in the field of antibody-drug conjugates (ADCs), comprehensively showcasing the company's R&D achievements in bispecific ADCs and dual-payload ADCs. It also shared a highly differentiated and globally competitive product pipeline and clinical development strategy, while outlini</description>
</item>
<item>
<title>Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-showcases-cutting-edge-breakthroughs-and-innovative-achievements-at-the-16th-world-adc-san-diego</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-showcases-cutting-edge-breakthroughs-and-innovative-achievements-at-the-16th-world-adc-san-diego</guid>
<pubDate>Thu, 06 Nov 2025 04:05:00 GMT</pubDate>
<description>The 16th World ADC San Diego, held from November 3–6, 2025, brought together industry leaders in San Diego, USA. Dr. Ting Xu, Founder, Chairman, and CEO of Alphamab Oncology, was invited to deliver a presentation titled "JSKN021: EGFR/HER3 Targeted Dual-payload ADC", showcasing the company's cutting-edge technological breakthroughs and innovative achievements in the ADC field to a global audience. The modularly designed dual-payload ADC platform technology and the prominent preclinical efficacy</description>
</item>
<item>
<title>Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-was-granted-fast-track-designation-by-fda-for-the-treatment-of-proc</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-was-granted-fast-track-designation-by-fda-for-the-treatment-of-proc</guid>
<pubDate>Tue, 28 Oct 2025 01:46:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (PROC), not restricted by HER2 expression. This marks another accelerated review recognition for JSKN003 from an internationally au</description>
</item>
<item>
<title>Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-received-approval-to-initiate-a-phase-iii-clinical-study-for-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-received-approval-to-initiate-a-phase-iii-clinical-study-for-colorectal-cancer</guid>
<pubDate>Mon, 27 Oct 2025 01:51:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (Study ID: JSKN003-005) for the treat</description>
</item>
<item>
<title>Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022</title>
<link>https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-i-clinical-study-of-pd-l1avb6-bispecfic-adc-jskn022</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-i-clinical-study-of-pd-l1avb6-bispecfic-adc-jskn022</guid>
<pubDate>Fri, 24 Oct 2025 04:56:00 GMT</pubDate>
<description>Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, for the treatment of advanced malignant solid tumors. JSKN022 is the Company's fourth ADC candidate entering clinical development, as well as the world's first PD-L1/αvβ6 bispecif</description>
</item>
<item>
<title>Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer</title>
<link>https://6ix.com/company/alphamab-oncology/news/biparatopic-her2-targeting-adc-jskn003-was-granted-another-breakthrough-therapy-designation-for-her2-positive-advanced-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/alphamab-oncology/news/biparatopic-her2-targeting-adc-jskn003-was-granted-another-breakthrough-therapy-designation-for-her2-positive-advanced-colorectal-cancer</guid>
<pubDate>Mon, 20 Oct 2025 05:21:00 GMT</pubDate>
<description>October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the indication of monotherapy for the treatment of HER2-positive advanced colorectal cancer (CRC) in patients who have failed</description>
</item>
</channel>
</rss>